St. Jude Children’s Research Hospital published a new assay that improves detection of small off-target edits produced by base editors. The team released the method to enable researchers and regulators to more precisely catalogue unintended genome modifications that pose safety risks for gene therapies. The paper emphasizes detection sensitivity for low-frequency sites that standard screens can miss. The authors detail a workflow to map tiny nucleotide-level edits across genomes, providing a quantitative readout that laboratories can adopt for preclinical safety testing. The method is positioned as a tool for both academic groups and biotech developers to validate editing specificity before clinical translation. St. Jude frames the approach as a way to reduce time and resources spent chasing false negatives in off-target discovery.